FILANA THERAPEUTICS INC (FLNA) Stock Price & Overview
NASDAQ:FLNA • US14817C1071
Current stock price
The current stock price of FLNA is 1.7 USD. Today FLNA is up by 1.8%.
FLNA Key Statistics
- Market Cap
- 82.11M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.45
- Dividend Yield
- N/A
FLNA Stock Performance
FLNA Stock Chart
FLNA Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to FLNA.
FLNA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to FLNA. While FLNA seems to be doing ok healthwise, there are quite some concerns on its profitability.
FLNA Earnings
FLNA Forecast & Estimates
FLNA Groups
Sector & Classification
FLNA Financial Highlights
Over the last trailing twelve months FLNA reported a non-GAAP Earnings per Share(EPS) of -1.45. The EPS increased by 37.5% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -81.73% | ||
| ROE | -129.99% | ||
| Debt/Equity | 0 |
FLNA Ownership
FLNA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 27.27 | 878.353B | ||
| JNJ | JOHNSON & JOHNSON | 20.72 | 574.237B | ||
| MRK | MERCK & CO. INC. | 23.8 | 294.907B | ||
| PFE | PFIZER INC | 9.2 | 154.155B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.35 | 117.443B | ||
| ZTS | ZOETIS INC | 16.92 | 49.305B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.27 | 27.037B | ||
| VTRS | VIATRIS INC | 5.41 | 15.152B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.43 | 11.336B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.631B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.37B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 6.073B | ||
| CORT | CORCEPT THERAPEUTICS INC | 50.68 | 4.435B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About FLNA
Company Profile
Cassava Sciences, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, investigational treatments for central nervous system disorders, including Alzheimer’s disease and tuberous sclerosis complex (TSC)-related seizures. The Company's science is based on stabilizing, but not removing, a critical protein in the brain for patients with disorders such as Alzheimer’s disease or TSC. It has two biopharmaceutical assets under development: Simufilam and SavaDx. Simufilam, its lead therapeutic product candidate, is an oral treatment for Alzheimer’s disease and TSC-related epilepsy. Simufilam targets an altered form of a protein called filamin A (FLNA) in the brain of patients with disorders such as Alzheimer’s disease or TSC. SavaDx, its lead investigational diagnostic product candidate, early-stage program focused on detecting the presence of Alzheimer’s disease from a small sample of blood.
Company Info
IPO: 2000-07-14
FILANA THERAPEUTICS INC
6801 N. Capital of Texas Highway, BUILDING 1; SUITE 300
Austin TEXAS US
Employees: 17
Phone: 13026587581
FILANA THERAPEUTICS INC / FLNA FAQ
What does FILANA THERAPEUTICS INC do?
Cassava Sciences, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, investigational treatments for central nervous system disorders, including Alzheimer’s disease and tuberous sclerosis complex (TSC)-related seizures. The Company's science is based on stabilizing, but not removing, a critical protein in the brain for patients with disorders such as Alzheimer’s disease or TSC. It has two biopharmaceutical assets under development: Simufilam and SavaDx. Simufilam, its lead therapeutic product candidate, is an oral treatment for Alzheimer’s disease and TSC-related epilepsy. Simufilam targets an altered form of a protein called filamin A (FLNA) in the brain of patients with disorders such as Alzheimer’s disease or TSC. SavaDx, its lead investigational diagnostic product candidate, early-stage program focused on detecting the presence of Alzheimer’s disease from a small sample of blood.
Can you provide the latest stock price for FILANA THERAPEUTICS INC?
The current stock price of FLNA is 1.7 USD. The price increased by 1.8% in the last trading session.
Does FILANA THERAPEUTICS INC pay dividends?
FLNA does not pay a dividend.
What is the ChartMill rating of FILANA THERAPEUTICS INC stock?
FLNA has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the sector and industry classification for FILANA THERAPEUTICS INC?
FILANA THERAPEUTICS INC (FLNA) operates in the Health Care sector and the Pharmaceuticals industry.
What is the employee count for FLNA stock?
FILANA THERAPEUTICS INC (FLNA) currently has 17 employees.